Jan van de Winkel & Ramona Sequeira Nominated To Novo Nordisk Board
Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira for election to its Board of Directors.
Winkel is Co-Founder and Chief Executive Officer (CEO) of Genmab. He previously served as President, Research and Development and Chief Scientific Officer before becoming CEO in 2010. He has over 25 years of experience in therapeutic antibodies and earlier worked as Vice President and Scientific Director at Medarex Europe. He has authored more than 300 scientific publications and contributed to over 150 patents and patent applications. He holds a professorship in immunotherapy at Utrecht University and earned M.S. and Ph.D. degrees from Radboud University Nijmegen. He is a registered manager of Genmab with the Danish Business Authority.
Sequeira is a member of the Global Executive Team at Takeda Pharmaceutical and serves as President of its Global Portfolio Division. She leads regional business units across Europe and Canada, Growth and Emerging Markets, and China, along with the Global Vaccines Business Unit and global medical and product strategy functions. She joined Takeda in 2015 to head its U.S. Business Unit. Sequeira served for seven years on the Board of PhRMA, including as chair. She is a Board Member at Edwards Lifesciences and previously served on the Board of Harvey Mudd College. She holds an MBA from McMaster University and a science degree from University of Toronto.
